EYEN (Eyenovia) EBIT per Share : $-0.67 (TTM As of Sep. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Eyenovia EBIT per Share?

Eyenovia's EBIT per Share for the three months ended in Sep. 2024 was $-0.11. Its EBIT per Share for the trailing twelve months (TTM) ended in Sep. 2024 was $-0.67.

During the past 3 years, the average EBIT per Share Growth Rate was 13.00% per year. During the past 5 years, the average EBIT per Share Growth Rate was 20.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for Eyenovia's EBIT per Share or its related term are showing as below:

EYEN' s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -61.8 Med: -4.55 Max: 35.2
Current: 13

During the past 9 years, the highest 3-Year average EBIT per Share Growth Rate of Eyenovia was 35.20% per year. The lowest was -61.80% per year. And the median was -4.55% per year.

EYEN's 3-Year EBIT Growth Rate is ranked better than
64.08% of 1250 companies
in the Biotechnology industry
Industry Median: 2.8 vs EYEN: 13.00

Eyenovia's EBIT for the three months ended in Sep. 2024 was $-7.29 Mil.

Eyenovia EBIT per Share Historical Data

The historical data trend for Eyenovia's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Eyenovia EBIT per Share Chart

Eyenovia Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EBIT per Share

Get a 7-Day Free Trial

-1.47

-0.94

-0.47

-0.79

-0.61

Eyenovia Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
EBIT per Share	Get a 7-Day Free Trial															-0.17	-0.15	-0.22	-0.20	-0.11

Eyenovia EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

Eyenovia's EBIT per Share for the fiscal year that ended in Dec. 2023 is calculated as

	EBIT per Share		(A: Dec. 2023 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-24.889	/	41.033
=	-0.61

Eyenovia's EBIT per Share for the quarter that ended in Sep. 2024 is calculated as

	EBIT per Share		(Q: Sep. 2024 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-7.286	/	69.558
=	-0.10

EBIT per Share for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.67

Eyenovia (NAS:EYEN) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

Eyenovia EBIT per Share Related Terms

Thank you for viewing the detailed overview of Eyenovia's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Eyenovia Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Eyenovia Inc (NAS:EYEN) » Definitions » EBIT per Share

Comparable Companies

Traded in Other Exchanges

N/A

Address

295 Madison Avenue, Suite 2400, New York, NY, USA, 10017

Website

https://www.eyenovia.com

Eyenovia Inc is a clinical stage ophthalmic company developing a pipeline of therapeutics based on its propriety array print (MAP) platform technology. It aims to achieve clinical microdosing of next-generation formulations of novel and existing ophthalmic pharmaceutical agents using its high-precision targeted ocular delivery system, branded the Opejet, which has the potential to replace conventional eye dropper delivery and improve safety, tolerability, patient compliance and topical delivery success for ophthalmic eye treatments. Using its proprietary delivery technology, Eyenovia is developing the next generation of smart ophthalmic therapies which target new indications or new combinations.

Executives

Michael M Rowe	director, officer: Chief Executive Officer	C/O EYENOVIA, INC., 501 FIFTH AVENUE, SUITE 1404, NEW YORK NY 10017
Stuart M. Grant	10 percent owner	11 SUMMIT LANE, GREENVILLE DE 19807
Ellen R Strahlman	director	ALTRIA GROUP, INC., 6601 W. BROAD STREET, RICHMOND VA 23230
Ram Palanki	director	C/O EYENOVIA, INC, 295 MADISON AVENUE SUITE 2400, NEW YORK NY 10017
Rachel Jacobson	director	C/O EYENOVIA INC, 295 MADISON AVENUE SUITE 2400, NEW YORK NY 10017
John P Gandolfo	officer: Chief Financial Officer	62 TERRACE ROAD, WAYNE NJ 07470
Bren Kern	officer: Chief Operating Officer	295 MADISON AVENUE, SUITE 2400, C/O EYENOVIA, INC., NEW YORK NY 10017
Mather Charles E Iv	director	C/O TONIX PHARMACEUTICALS HOLDING CORP, 509 MADISON AVE., SUITE 306, NEW YORK NY 10022
Tsontcho Ianchulev	director	501 FIFTH AVENUE, SUITE 1404, NEW YORK NY 10017
Stephen Keith Benjamin	director	135 NORTH CHURCH STREET, SPARTANBURG SC 29306
Julia A Haller	director	C/O CELGENE CORPORATION, 86 MORRIS AVENUE, SUMMIT NJ 07901
Lee Kenneth B Jr	director	7100 WEST CREDIT AVENUE, SUITE 101, C/O ARALEZ PHARMACEUTICALS INC., MISSISSAUGA A6 L5N 0E4
Curt H Labelle	director	C/O INVESTOR GROWTH CAPITAL, INC., 630 FIFTH AVENUE, SUITE 1965, NEW YORK NY 10011
Anthony Y Sun	director	C/O AISLING CAPITAL, 888 SEVENTH AVENUE, 30TH FLOOR, NEW YORK NY 10106
Fredric N Eshelman	director	PPD INC, 929 NORTH FRONT STREET, WILMINGTON NC 28401